http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 11 Jun 2026 08:03:11 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html <p>60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) signed an exclusive patent licensing agreement with Florida State University for non-prescription use of Australian chestnut extract as a botanical supplement, the company announced.</p> <p>The license allows the pharmaceutical company to begin large-scale extraction of castanospermine from the seeds of Castanospermum australe, commonly known as the Australian Chestnut. Castanospermine serves as the principal component of Australian Chestnut Extract.</p> <p>The U.S. Food and Drug Administration issued a Non-Notification Letter to 60 Degrees Pharmaceuticals regarding the company's New Dietary Ingredient Notification filing for Australian Chestnut Extract. The company will meet with the FDA on July 1, 2026, to http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html Thu, 11 Jun 2026 08:03:11 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html <p>60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) signed an exclusive patent licensing agreement with Florida State University for non-prescription use of Australian chestnut extract as a botanical supplement, the company announced.</p> <p>The license allows the pharmaceutical company to begin large-scale extraction of castanospermine from the seeds of Castanospermum australe, commonly known as the Australian Chestnut. Castanospermine serves as the principal component of Australian Chestnut Extract.</p> <p>The U.S. Food and Drug Administration issued a Non-Notification Letter to 60 Degrees Pharmaceuticals regarding the company's New Dietary Ingredient Notification filing for Australian Chestnut Extract. The company will meet with the FDA on July 1, 2026, to http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html Thu, 11 Jun 2026 08:03:11 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html <p>60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) signed an exclusive patent licensing agreement with Florida State University for non-prescription use of Australian chestnut extract as a botanical supplement, the company announced.</p> <p>The license allows the pharmaceutical company to begin large-scale extraction of castanospermine from the seeds of Castanospermum australe, commonly known as the Australian Chestnut. Castanospermine serves as the principal component of Australian Chestnut Extract.</p> <p>The U.S. Food and Drug Administration issued a Non-Notification Letter to 60 Degrees Pharmaceuticals regarding the company's New Dietary Ingredient Notification filing for Australian Chestnut Extract. The company will meet with the FDA on July 1, 2026, to http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html Thu, 11 Jun 2026 08:03:11 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html <p>60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) signed an exclusive patent licensing agreement with Florida State University for non-prescription use of Australian chestnut extract as a botanical supplement, the company announced.</p> <p>The license allows the pharmaceutical company to begin large-scale extraction of castanospermine from the seeds of Castanospermum australe, commonly known as the Australian Chestnut. Castanospermine serves as the principal component of Australian Chestnut Extract.</p> <p>The U.S. Food and Drug Administration issued a Non-Notification Letter to 60 Degrees Pharmaceuticals regarding the company's New Dietary Ingredient Notification filing for Australian Chestnut Extract. The company will meet with the FDA on July 1, 2026, to http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html Thu, 11 Jun 2026 08:03:11 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html <p>60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) signed an exclusive patent licensing agreement with Florida State University for non-prescription use of Australian chestnut extract as a botanical supplement, the company announced.</p> <p>The license allows the pharmaceutical company to begin large-scale extraction of castanospermine from the seeds of Castanospermum australe, commonly known as the Australian Chestnut. Castanospermine serves as the principal component of Australian Chestnut Extract.</p> <p>The U.S. Food and Drug Administration issued a Non-Notification Letter to 60 Degrees Pharmaceuticals regarding the company's New Dietary Ingredient Notification filing for Australian Chestnut Extract. The company will meet with the FDA on July 1, 2026, to http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html Thu, 11 Jun 2026 08:03:11 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html <p>60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) signed an exclusive patent licensing agreement with Florida State University for non-prescription use of Australian chestnut extract as a botanical supplement, the company announced.</p> <p>The license allows the pharmaceutical company to begin large-scale extraction of castanospermine from the seeds of Castanospermum australe, commonly known as the Australian Chestnut. Castanospermine serves as the principal component of Australian Chestnut Extract.</p> <p>The U.S. Food and Drug Administration issued a Non-Notification Letter to 60 Degrees Pharmaceuticals regarding the company's New Dietary Ingredient Notification filing for Australian Chestnut Extract. The company will meet with the FDA on July 1, 2026, to http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html Thu, 11 Jun 2026 08:03:11 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html <p>60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) signed an exclusive patent licensing agreement with Florida State University for non-prescription use of Australian chestnut extract as a botanical supplement, the company announced.</p> <p>The license allows the pharmaceutical company to begin large-scale extraction of castanospermine from the seeds of Castanospermum australe, commonly known as the Australian Chestnut. Castanospermine serves as the principal component of Australian Chestnut Extract.</p> <p>The U.S. Food and Drug Administration issued a Non-Notification Letter to 60 Degrees Pharmaceuticals regarding the company's New Dietary Ingredient Notification filing for Australian Chestnut Extract. The company will meet with the FDA on July 1, 2026, to http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+licenses+Australian+chestnut+patent/26632911.html Thu, 11 Jun 2026 08:03:11 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html <ul type="disc"><li><strong>License allows the Company to commence large-scale extraction of castanospermine from the seeds of </strong><strong><em>Castanospermum australe</em></strong> </li><li><strong>Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.<br/></strong><br/></li></ul> <p>WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=7HPu3tzSaKK5hbhXguUDBCuSLxVeSZ2ptMkDkakqd5_JRtOHEzRK9HdWy0W6m9va_VpnQ4DS1CAY7i1ngGyQWcLqWlXc5jovLGOnxGzmmOHhvFOMz6aCT872GBmqTdUaemtg8hyihkx7h9re3g3rug==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Signs+Exclusive+Patent+License+Agreement+with+Florida+State+University+for+Non-Prescription+Use+of+Australian+Chestnut+Extract+as+a+Botanical+Supplement/26632907.html Thu, 11 Jun 2026 08:03:00 -0400 A.06822034 A.12219044 O.20026344 O.20300557 O.58280676 SXTP SXTPW http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+enrolls+first+patient+in+tafenoquine+babesiosis+trial/26546286.html <p>60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) has enrolled the first patient of the 2026 tick season in its clinical trial evaluating tafenoquine for treating babesiosis in hospitalized patients, according to a company statement.</p><p>The randomized, double-blind, placebo-controlled trial (NCT06207370) is being conducted at five clinical sites in the northeastern United States. The study will enroll at least 24 patients before conducting an interim analysis, with two primary endpoints: time to clinical symptom resolution and parasite clearance.</p><p>Enrollment is proceeding approximately one month ahead of schedule, which could allow the company to reach minimum enrollment for interim analysis as early as July 2026. http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+enrolls+first+patient+in+tafenoquine+babesiosis+trial/26546286.html Tue, 26 May 2026 08:03:23 -0400 SXTP SXTPW http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+enrolls+first+patient+in+tafenoquine+babesiosis+trial/26546286.html <p>60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) has enrolled the first patient of the 2026 tick season in its clinical trial evaluating tafenoquine for treating babesiosis in hospitalized patients, according to a company statement.</p><p>The randomized, double-blind, placebo-controlled trial (NCT06207370) is being conducted at five clinical sites in the northeastern United States. The study will enroll at least 24 patients before conducting an interim analysis, with two primary endpoints: time to clinical symptom resolution and parasite clearance.</p><p>Enrollment is proceeding approximately one month ahead of schedule, which could allow the company to reach minimum enrollment for interim analysis as early as July 2026. http://www.streetinsider.com/Corporate+News/60+Degrees+Pharmaceuticals+enrolls+first+patient+in+tafenoquine+babesiosis+trial/26546286.html Tue, 26 May 2026 08:03:23 -0400 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Early+Enrollment+of+First+Seasonal+Patient+in+Clinical+Trial+of+Tafenoquine+for+Patients+Hospitalized+with+Babesiosis/26546272.html <ul><li style="text-align:left;">Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones</li><li style="text-align:left;">Minimum enrollment to support interim analysis expected as soon as early July 2026</li><li style="text-align:left;">Randomized, double-blind, placebo-controlled trial is evaluating the efficacy and safety of <strong>tafenoquine</strong> in treating humans hospitalized with babesiosis at five clinical sites in northeastern U.S.<br/><br/></li></ul> <p align="left">WASHINGTON, May 26, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=eJ2OiMTxf1WLRmCrNgiPtEoOAtRc6_9kD1i7JAzQh4LTEvhwg1mQ2mTnnFKXhIpxxF2F5FrIVh0PmgwaJF0gmMDxzgax7ZzRQqTrCt-I60px2VyzDypmJAHbseSvmXZyl7YZioN_tUQvbzEUIuejng==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or 60 Degrees Pharmaceuticals), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the first patient of the 2026 tick season has been enrolled http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Early+Enrollment+of+First+Seasonal+Patient+in+Clinical+Trial+of+Tafenoquine+for+Patients+Hospitalized+with+Babesiosis/26546272.html Tue, 26 May 2026 08:02:00 -0400 A.14320728 O.20250741 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Early+Enrollment+of+First+Seasonal+Patient+in+Clinical+Trial+of+Tafenoquine+for+Patients+Hospitalized+with+Babesiosis/26546272.html <ul><li style="text-align:left;">Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones</li><li style="text-align:left;">Minimum enrollment to support interim analysis expected as soon as early July 2026</li><li style="text-align:left;">Randomized, double-blind, placebo-controlled trial is evaluating the efficacy and safety of <strong>tafenoquine</strong> in treating humans hospitalized with babesiosis at five clinical sites in northeastern U.S.<br/><br/></li></ul> <p align="left">WASHINGTON, May 26, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=eJ2OiMTxf1WLRmCrNgiPtEoOAtRc6_9kD1i7JAzQh4LTEvhwg1mQ2mTnnFKXhIpxxF2F5FrIVh0PmgwaJF0gmMDxzgax7ZzRQqTrCt-I60px2VyzDypmJAHbseSvmXZyl7YZioN_tUQvbzEUIuejng==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (the “Company” or 60 Degrees Pharmaceuticals), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the first patient of the 2026 tick season has been enrolled http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Early+Enrollment+of+First+Seasonal+Patient+in+Clinical+Trial+of+Tafenoquine+for+Patients+Hospitalized+with+Babesiosis/26546272.html Tue, 26 May 2026 08:02:00 -0400 A.14320728 O.20250741 O.58280676 SXTP SXTPW